Woman is holding the textile home made face mask used for protection against viruses while walking in the nature. Symbol for protest against regulations or freedom after end of pandemic.
According to results from lab studies, an antibody-based COVID-19 therapy developed by GSK and Vir Biotechnology preserves neutralising activity against the developing BA.2 type of the Omicron coronavirus variant.
The business stated it would reveal preprint data in the coming week, followed by live viral data.
According to the business, the 500 mg dose of sotrovimab is sufficient to maintain action against the BA.2 variation, which is in line with all other variants of concern and interest, based on pseudovirus and substantial pharmacokinetic data.
Sotrovimab is one of the few COVID-19 therapies that has been demonstrated to act against the fast-spreading Omicron form, which has sparked interest. In 2021, it was one of GSK’s best-selling products.
Recent Posts
Harmful Bacteria in the Human Body: Risks and Prevention
The human body is home to trillions of bacteria, many of which are beneficial for…
Sitting vs. Walking: How 20 Minutes Affects Your Brain
In today’s fast-paced world, sedentary behavior has become a major health concern. Whether it’s working…
India’s Medical Tourism Industry to Reach $18 Billion by 2027
India’s medical tourism industry is on an accelerated growth path, with projections estimating that it…
Why Do Pregnant Women Forget? The Science Behind ‘Momnesia’
Pregnancy is a transformative journey, both physically and emotionally. It brings about significant hormonal, neurological,…
India Reports Highest Tuberculosis Cases in 2024 Amid Progress in TB Control
India has recorded its highest-ever number of tuberculosis (TB) cases in 2024, with 26.07 lakh…
Elon Musk’s 120-Hour Workweek: The Dark Reality
Elon Musk is known for his relentless work ethic and high expectations from his teams.…